Reuters logo
BRIEF-Sorrento Therapeutics says FDA authorizes co's IND for RTX
June 29, 2017 / 6:20 PM / 5 months ago

BRIEF-Sorrento Therapeutics says FDA authorizes co's IND for RTX

June 29 (Reuters) - Sorrento Therapeutics Inc:

* Sorrento Therapeutics announced FDA authorization of IND to commence clinical trial of RTX in intractable cancer pain

* Intends to initiate Phase 1b clinical trial of RTX administered by epidural injection for treatment of cancer associated pain Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below